ORF32-04 - Once Daily Atumelnant (CRN04894) Enables Lowering of Glucocorticoid Doses with Sustained Androgen Reduction in Adults with Congenital Adrenal Hyperplasia

Oral Abstract Presenter(s)

• US

  Umasuthan Srirangalingam, FRCP, PhD

  University College London Hospitals
  London, England, United Kingdom

Co-Author(s)

• DB

  Dario Bruera, MD

  Hospital Misericordia
  Córdoba, Argentina
• AR

  Adriane Maria Rodrigues, MD, PhD

  Universidade Federal do Paraná
  Curitiba, United States
• AA

  Alejandro Ayala, MD

  Crinetics Pharmaceuticals
  San Diego, California, United States
• YW

  Yang Wu, PhD

  Crinetics Pharmaceuticals
  San Diego, United States
• ED

  Eduardo De la Torre Ames, MD

  Crinetics Pharmaceuticals
  San Diego, California, United States
• AK

  Alan Krasner, MD (he/him/his)

  Chief Endocrinologist
  Crinetics Pharmaceuticals, Inc.
  Encinitas, CA, United States
• PT

  Peter J. Trainer, MD

  Crinetics Pharmaceuticals
  San Diego, California, United States
• MG

  Monica R. Gadelha, MD, PhD

  Centro de Pesquisa Clínica, Instituto Estadual do Cérebro Paulo Niemeyer
  Rio de Janeiro, Brazil
• 

  Nicole Reisch, MD, PhD

  Head of Clinical Endocrinology
  Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München
  Munich, Bayern, Germany
• FC

  Flavia Amanda Costa-Barbosa, MD, PhD

  Adrenal and Hypertension Unit, Division of Endocrinology and Metabolism, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo
  São Paulo, United States
• Vd

  Vania dos Santos Nunes-Nogueira, MD, PhD

  Department of Internal Medicine, São Paulo State University (UNESP), Medical School
  Botucatu, São Paulo, United States
• 

  Richard J. Auchus, MD,PhD

  Professor
  University of Michigan
  Ann Arbor, MI, United States
• TB

  Tania A.S.S. Bachega, MD, PhD (she/her/hers)

  Laboratorio de Hormonios e Genetica Molecular-LIM 42, da Faculdade de Medicina da Universidade de São Paulo
  Sao Paulo, Brazil